ING Groep NV Has $450,000 Position in Globus Medical Inc (GMED)

ING Groep NV increased its position in shares of Globus Medical Inc (NYSE:GMED) by 23.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,938 shares of the medical device company’s stock after acquiring an additional 2,095 shares during the period. ING Groep NV’s holdings in Globus Medical were worth $450,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its position in Globus Medical by 1.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,036 shares of the medical device company’s stock valued at $100,000 after buying an additional 35 shares in the last quarter. New York State Common Retirement Fund boosted its position in Globus Medical by 3.4% in the second quarter. New York State Common Retirement Fund now owns 75,900 shares of the medical device company’s stock valued at $2,516,000 after buying an additional 2,499 shares in the last quarter. Citigroup Inc. boosted its position in Globus Medical by 2.8% in the second quarter. Citigroup Inc. now owns 5,950 shares of the medical device company’s stock valued at $197,000 after buying an additional 161 shares in the last quarter. California Public Employees Retirement System boosted its position in Globus Medical by 10.0% in the second quarter. California Public Employees Retirement System now owns 84,700 shares of the medical device company’s stock valued at $2,808,000 after buying an additional 7,700 shares in the last quarter. Finally, Advisor Group Inc. boosted its position in Globus Medical by 2.0% in the second quarter. Advisor Group Inc. now owns 3,434 shares of the medical device company’s stock valued at $114,000 after buying an additional 68 shares in the last quarter. Institutional investors and hedge funds own 69.67% of the company’s stock.

GMED has been the topic of a number of research analyst reports. BTIG Research restated a “buy” rating and issued a $37.00 target price on shares of Globus Medical in a research report on Thursday, November 9th. Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a research report on Thursday, November 9th. Barclays raised their target price on shares of Globus Medical from $27.00 to $29.00 and gave the company an “underweight” rating in a research report on Thursday, November 9th. Canaccord Genuity restated a “buy” rating and issued a $38.00 target price on shares of Globus Medical in a research report on Thursday, November 9th. Finally, Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating in a research report on Friday, November 10th. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $40.57.

In other news, CAO Steven Payne sold 3,076 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $39.30, for a total transaction of $120,886.80. Following the completion of the transaction, the chief accounting officer now owns 23,847 shares of the company’s stock, valued at $937,187.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Anthony L. Williams sold 15,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $38.30, for a total transaction of $574,500.00. Following the transaction, the president now directly owns 15,000 shares of the company’s stock, valued at approximately $574,500. The disclosure for this sale can be found here. Insiders have sold 73,459 shares of company stock valued at $2,947,260 in the last ninety days. Insiders own 28.21% of the company’s stock.

Globus Medical Inc (NYSE:GMED) opened at $48.22 on Friday. The stock has a market cap of $4,647.25, a price-to-earnings ratio of 43.84, a PEG ratio of 2.82 and a beta of 0.48. Globus Medical Inc has a 52 week low of $26.95 and a 52 week high of $48.40.

TRADEMARK VIOLATION WARNING: “ING Groep NV Has $450,000 Position in Globus Medical Inc (GMED)” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/02/18/ing-groep-nv-has-450000-position-in-globus-medical-inc-gmed.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply